A Study of ICP-022 in Patients With R/R DLBCL

NCT04438005 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG: ICP-022

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.